세계 인슐린 펌프 시장 규모는 2023년 67억 8,000만 달러에서 예측 기간 동안 12.28%의 CAGR로 2031년에는 171억 2,000만 달러 규모로 성장할 것으로 예상됩니다.
시장 성장을 이끄는 주요 요인으로는 당뇨병 유병률 급증, 편의성과 사용 편의성을 제공하는 인슐린 전달 장치에 대한 수요 증가, 기술 발전, 정부의 노력, 노인 인구 증가 등이 있습니다.
지난 30년간 전 세계 당뇨병 환자 수는 1억 800만 명에서 4억 2,000만 명으로 급증했습니다. 이 중 6,200만 명이 북미와 남미의 당뇨병 환자이며, 이는 세계 인슐린 펌프 시장에 큰 영향을 미치고 있습니다. 주목할 만한 점은 1980년 이후 이 지역의 당뇨병 환자 수가 3배 이상 증가했기 때문에 실제 수치는 이보다 더 높을 가능성이 높다는 것입니다. 당뇨병과 관련된 건강 문제로 인한 부담은 심각하며, 20년 동안 당뇨병 관련 사망률은 전 세계적으로 70%나 증가했습니다.
인슐린 자동 투여 알고리즘에 대한 요구가 증가함에 따라 당뇨병 치료의 중요한 전환이 이루어지고 있습니다. 첨단 기술을 기반으로 한 이러한 알고리즘은 정확하고 적응력이 높은 인슐린 조절을 제공합니다. 전 세계적으로 당뇨병 유병률이 증가함에 따라 인슐린 관리를 간소화하고 개선할 수 있는 독창적인 솔루션에 대한 수요가 증가하고 있습니다.
정부의 노력은 접근성, 가격, 첨단 기술 도입에 영향을 미치고 있으며, 인슐린 펌프 시장의 특성을 형성하는 데 핵심적인 역할을 하고 있습니다. 이러한 정부의 노력은 전 세계 수많은 인구를 괴롭히는 당뇨병 문제를 해결하기 위해 필수적입니다. 정부가 환자의 자가 관리를 지원하는 정도가 높을수록 장기적인 의료 비용을 줄일 수 있습니다.
세계 인슐린 펌프 시장을 조사했으며, 시장 정의와 개요, 시장 규모 추이 및 예측, 각종 부문별·지역별 상세 분석, 산업 구조, 시장 성장에 영향을 미치는 요인 분석, 사례 연구, 경쟁 상황, 주요 기업 개요 등의 정보를 정리하여 전해드립니다.
Global insulin pumps market size was valued at USD 6.78 billion in 2023, which is expected to reach USD 17.12 billion in 2031, with a CAGR of 12.28% for the forecast period between 2024 and 2031F. The key factors propelling the global insulin pumps market include a surge in the prevalence of diabetes, a growing need for insulin delivery devices that offer convenience and user-friendliness, advancements in technology, governmental efforts, and an increasing elderly population.
The global insulin pumps market is expected to gain a substantial transformation and expansion, driven by a convergence of factors that are reshaping the realm of diabetes management. One of the principal catalysts propelling the market's growth is the escalating prevalence of diabetes. The alarming surge in diabetes cases, encompassing both type 1 and type 2, has generated an urgent requirement for dependable and convenient means of administering insulin. As patients and healthcare practitioners seek more efficacious methods for regulating blood glucose levels, insulin pumps have emerged as the favored choice due to their capacity to deliver precise doses with minimal exertion.
Moreover, the global insulin pumps market is capitalizing on technological advancements. The incorporation of continuous glucose monitoring (CGM), the emergence of intelligent insulin pumps, and improvements in user interfaces have transformed these devices into more user-friendly and efficient tools. Patients are increasingly in search of devices that provide precise insulin delivery and seamlessly integrate with smartphones and other digital platforms, enabling real-time data monitoring and management.
Additionally, governmental efforts aimed at alleviating the diabetes burden and associated healthcare costs are fostering the global insulin pumps market's growth. Public health initiatives and policies designed to encourage the adoption of advanced diabetes management technologies have contributed to heightened accessibility and affordability of insulin pumps.
Globally, the population of individuals living with diabetes (PLWD) has witnessed a substantial surge over the past three decades, soaring from 108 million to 420 million. Among these, 62 million individuals with diabetes reside in the Americas, largely impacting the global insulin pumps market. Notably, the number has ballooned by more than threefold in the region since 1980, with the actual figure being potentially higher, as 40% of PLWD remain unaware of their condition, going undiagnosed. The burden posed by diabetes-related health issues is both significant and escalating. Within two decades, diabetes-related mortality has escalated by a staggering 70% worldwide.
In the Americas, it stands as the sixth leading cause of death and the seventh leading contributor to years of life lost prematurely. In the region, diabetes, inclusive of diabetes-related kidney disease, accounts for the premature loss of more than eight million years of life annually. Astonishingly, almost half of premature deaths in the Americas are attributed to diabetes. Furthermore, over a span of just 20 years, the number of disability-adjusted life years (DALYs) attributable to diabetes has surged by 88%, reaching a remarkable 97% increase among men. Presently, diabetes ranks as the second leading cause of DALYs globally, trailing behind ischemic heart disease.
The increasing desire for algorithms in automated insulin delivery signifies a significant shift in diabetes care. These algorithms, powered by advanced technologies, offer precise and adaptable insulin control. With the global diabetes prevalence on the rise, there's a pronounced demand for inventive solutions to simplify and improve insulin management. The growing demand for insulin delivery algorithms is opening doors for companies specializing in these technologies. Firms capable of creating precise, dependable, and user-friendly algorithms are poised to thrive in the expanding global insulin pumps market. As an example, in May 2023, Beta Bionics obtained approval from the US Food and Drug Administration (FDA) for its iLet ACE Pump and iLet Dosing Decision Software, designed for individuals aged six years and older with type 1 diabetes. These components, when used in conjunction with a compatible integrated continuous glucose monitor (iCGM), constitute the iLet Bionic Pancreas system. The innovative system employs an algorithm to assess and regulate insulin delivery.
Government actions are central in molding the global insulin pumps market's characteristics, impacting its accessibility, affordability, and the uptake of advanced technologies for managing diabetes. These governmental endeavors are vital in confronting the escalating issue of diabetes, a persistent metabolic ailment marked by elevated blood glucose levels that afflict a vast global population. The greater the extent to which governments can assist patients in acquiring the skills for self-management, the lower the long-term healthcare costs it will incur due to improved health outcomes and reduced costs for the entire population.
For instance, in March 2023, the government of New Brunswick unveiled its plan to alleviate the financial burden associated with diabetes. Minister of Finance Ernie Steeves announced a budget allocation of USD 2.1 million to improve diabetes management. In New Brunswick, annual expenses directly borne by individuals can surpass USD 18,000 for those with Type 1 diabetes and USD 10,000 for those with Type 2 diabetes, as reported by Diabetes Canada. The province's announcement is expected to target and alleviate a significant portion of the high costs linked with diabetes.
The increasing desire for insulin patches marks a noteworthy transformation in the global insulin pump market. Insulin patches present a non-intrusive and unobtrusive means of administering insulin, potentially enhancing the well-being of individuals living with diabetes. The surging appeal of these patches can be traced to their convenience, precision, and ability to address certain obstacles linked to conventional insulin delivery approaches.
As an illustration, in May 2023, Medtronic plc, a prominent player in healthcare technology, disclosed its intent to finalize a series of agreements aimed at acquiring EOFlow Co. Ltd., the creator of the EOPatch device, an insulin delivery device that is both tubeless and disposable, designed to be worn on the body. The incorporation of EOFlow into Medtronic's portfolio, in conjunction with the company's Meal Detection Technology algorithm and state-of-the-art continuous glucose monitor (CGM), is poised to enhance Medtronic's capacity to cater to the diverse requirements of individuals with diabetes, regardless of their stage in the treatment process or their preferences for insulin delivery methods. Such convenience-based products are the leading cause for drastic growth in global insulin pump market.
The intricate challenges of mealtimes in type 1 diabetes management drive the demand for solutions and stimulate growth in the global insulin pumps market. Balancing insulin dosages with carbohydrate intake, managing blood sugar spikes post-meal, and predicting meal content can be formidable tasks. The challenge lies in maintaining glycemic control and preventing hypoglycemia or hyperglycemia during and after meals. CGM, advanced insulin delivery systems, and mealtime planning have become essential strategies to address these challenges and enhance diabetes management. As an example, in April 2023, Medtronic plc, a leading global medical technology company, revealed that the U.S. Food and Drug Administration (FDA) had approved its MiniMed 780G system, featuring the Guardian 4 sensor, which eliminates the need for fingerstick tests when using SmartGuard technology. This achievement signifies the approval of the sole system incorporating meal detection technology, enabling automatic adjustments and corrections to sugar levels every 5 minutes, proving highly advantageous for individuals with type 1 diabetes.
Patients with T1DM using insulin pumps experienced a milder impact from COVID-19 lockdown measures on their glycemic control than those using insulin pens. The adoption of telemedicine and online consultations yielded substantial benefits, optimizing time allocation per patient, and improving physician-patient communication. Physicians could remotely monitor disease progression, resulting in significant improvements. Notably, insulin pump users exhibited superior glycemic stability and better resilience to pandemic-related stress and anxiety compared to pen users. The advantage may be attributed to the continuous glycemic monitoring system, which is likely contributed to fewer hyperglycemic episodes in the group. However, the pandemic had some adverse effects on the global insulin pumps market, as several insulin pump manufacturers deferred or put on hold the introduction of new products or enhancements because of the uncertainties stemming from the pandemic.
Collaborative efforts in the global insulin pumps market are witnessing a surge as companies aim to pioneer novel and inventive technologies for the betterment of individuals with diabetes. Recent instances of such collaborations include Medtronic teaming up with Bigfoot Biomedical to co-create a hybrid closed-loop insulin delivery system, and Tandem Diabetes Care partnering with Dexcom to seamlessly integrating their insulin pumps with Dexcom's continuous glucose monitoring (CGM) system. These partnerships are pivotal in expediting the development of next-generation insulin pumps characterized by enhanced accuracy, convenience, and user-friendliness.
For example, in August 2023, Modular Medical, Inc. joined forces with Phillips-Medisize to broaden the array of insulin delivery options. Leveraging its extensive and diverse supplier network, as well as its profound expertise in medical devices and diabetes management, Phillips-Medisize took charge of designing and developing the manufacturing and assembly processes for the MODD1 Insulin Delivery System. The collaboration has expedited the development journey for Modular Medical and has paved the way for substantial scalability and a state of readiness for market launch.
All segments will be provided for all regions and countries covered:
Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.